|
|
 | | | |
- close
- close
- close
- close
| |||||||||
AMLN » Topics » If our research and development programs fail to result in additional drug candidates, our ability to generate revenue will be substantially limited.This excerpt taken from the AMLN 10-K filed Feb 26, 2010. If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired. Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us. This excerpt taken from the AMLN 10-Q filed May 11, 2009. If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.
Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.
These excerpts taken from the AMLN 10-K filed Feb 27, 2009. If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired. Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us. Certain of our research and development programs for drug candidates are at an early stage and will require significant research, This excerpt taken from the AMLN 10-Q filed Nov 4, 2008. If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.
Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.
This excerpt taken from the AMLN 10-Q filed Jul 31, 2008. If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.
Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.
This excerpt taken from the AMLN 10-Q filed May 2, 2008. If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.
Certain of our research and development programs for drug candidates are at an early stage and will require significant
27
research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.
These excerpts taken from the AMLN 10-K filed Feb 27, 2008. If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.
Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.
If our research and development programs fail to result in
Certain of our research
This excerpt taken from the AMLN 10-Q filed Nov 6, 2007. If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired.
Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us.
This excerpt taken from the AMLN 10-Q filed Aug 7, 2007. If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired. Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us. This excerpt taken from the AMLN 10-Q filed May 2, 2007. If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired. Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us. This excerpt taken from the AMLN 10-K filed Feb 26, 2007. If our research and development programs fail to result in additional drug candidates, the growth of our business could be impaired. Certain of our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate additional revenues for us. This excerpt taken from the AMLN 10-Q filed Nov 6, 2006. If our research and development programs fail to result in additional drug candidates, our ability to generate revenue will be substantially limited. Our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate revenues for us. This excerpt taken from the AMLN 10-Q filed Aug 7, 2006. If our research and development programs fail to result in additional drug candidates, our ability to generate revenue will be substantially limited. Our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate revenues for us. This excerpt taken from the AMLN 10-Q filed May 5, 2006. If our research and development programs fail to result in additional drug candidates, our ability to generate revenue will be substantially limited.
Our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate revenues for us.
This excerpt taken from the AMLN 10-K filed Mar 7, 2006. If our research and development programs fail to result in additional drug candidates, our ability to generate revenue will be substantially limited.
Our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate revenues for us.
This excerpt taken from the AMLN 10-Q filed Nov 7, 2005. If our research and development programs fail to result in additional drug candidates, our ability to generate revenue will be substantially limited.
Our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate revenues for us.
This excerpt taken from the AMLN 10-Q filed Aug 8, 2005. If our research and development programs fail to result in additional drug candidates, our ability to generate revenue will be substantially limited.
Our research and development programs for drug candidates are at an early stage and will require significant research, development, preclinical and clinical testing, manufacturing scale-up activities, regulatory approval and/or commitments of resources before commercialization. We cannot predict whether our research will lead to the discovery of any additional drug candidates that could generate revenues for us.
| EXCERPTS ON THIS PAGE:RELATED TOPICS for AMLN:
|
| |||||||
